NCT01863550
Clinical Trial Information
Trial Number: NCT01863550 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Myeloma - Myeloma
Trial Title:
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Study ID:
E1A11
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01863550-D8 | This dataset, NCT01863550-D8, contains unpublished data on site enrollment, non-protocol therapy (NPT) status, time to NPT, and a new definition of progression-free survival that were collected on ECOG-ACRIN trial E1A11. Data from this trial’s primary publication (PMID 32866432) can be found in NCT01863550-D1 to NCT01863550-D7. Patients in all these data submissions have the same deidentified patient IDs. |
| NCT01863550-D7 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D7, contains patients reported quality-of-life data. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D6 contains secondary primary cancers. |
| NCT01863550-D6 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D6, contains secondary primary cancers. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
| NCT01863550-D5 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D5, contains adverse events submitted via expedited reporting. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D6 contains secondary primary cancers. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
| NCT01863550-D4 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D4, contains toxicity data reported by case report forms. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D6 contains secondary primary cancers. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
| NCT01863550-D3 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D3, contains information related to first dose modification. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D6 contains secondary primary cancers. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
| NCT01863550-D2 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D1 contains baseline, treatment, and efficacy data. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D6 contains secondary primary cancers. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
| NCT01863550-D1 | There are seven different submissions for PMID 32866432 from trial E1A11. This dataset, NCT01863550-D1, contains baseline, treatment, and efficacy data. Dataset NCT01863550-D2 contains treatment dose by cycle. Dataset NCT01863550-D3 contains information related to first dose modification. Dataset NCT01863550-D4 contains toxicity data reported by case report forms. Dataset NCT01863550-D5 contains adverse events submitted via expedited reporting. Dataset NCT01863550-D6 contains secondary primary cancers. Dataset NCT01863550-D7 contains patients reported quality-of-life data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®